18F-Fluorocholine (18F-FCho) to Distinguish Necrosis From Recurrence in Brain Metastases

N/ACompletedNCT02037945

Memorial Sloan Kettering Cancer Center19 enrolled

Overview

The main purpose of this study is to determine the distribution of 18F Fluorocholine (18F-FCH) in the brain which can help distinguishing radiation-induced scarring from tumor regrowth. In addition, the study will measure levels of 18F-FCH in the blood and (if applicable) in the brain lesion tissue that is removed as part of the planned brain surgery.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Brain Metastases

Interventions

18F-FCH PET ScanPROCEDURE

Eligibility

Sex: ALLMin age: 21 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient and/or guardian is able to provide written informed consent prior to study registration * Age ≥ 21 years old * Evolving brain lesions post SRS requiring neurosurgical resection (whether for symptomatic control or to establish pathology) Exclusion Criteria: * Inability to undergo a MRI or PET scan (e.g., claustrophobia or metal implant) * Pregnant or nursing female * Unable to cooperate for PET/CT

Locations (1)

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Outcomes

Primary Outcomes

to distinguish radiation necrosis from progressive tumor

by comparing the PET imaging results to the surgical pathology

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.